Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • Osteopore has partnered with Tan Tock Seng Hospital to co-develop a novel implant for the treatment of avascular necrosis (AVN) of the hip joint.

  • The collaboration is supported by a SGD 50,000 MedTech grant from NHG Health and will run for 12 months from September 2025.

  • The AVN treatment market is forecast to reach USD 10.2 billion by 2030, driven by increasing awareness, early diagnosis, and rising prevalence.

Osteopore Limited (ASX:OSX), an Australian-Singaporean regenerative medicine company, has entered into a co-development collaboration with Tan Tock Seng Hospital (TTSH) for the design of a novel implant aimed at treating avascular necrosis (AVN) of the hip joint. The project will be led by Dr Michael Yam Gui Jie, Consultant from the Department of Orthopaedic Surgery and Clinical Director of the Medical 3DP Centre at TTSH.

The initiative is supported by a SGD 50,000 MedTech grant awarded by NHG Health. The 12-month collaboration commenced in September 2025 and is expected to conclude with proof-of-concept validation and potential first-in-human milestones.

Understanding AVN and Market Opportunity

Avascular necrosis (AVN) occurs when blood supply to bone tissue is interrupted, leading to necrosis and, in severe cases, collapse of the bone. The condition most frequently affects the hip joint and can result in total hip replacement (THR) if untreated. Roughly 10% of AVN cases progress to THR, with between 20,000 and 30,000 new cases reported annually in the United States.

The global AVN treatment market is projected to reach USD 10.2 billion by 2030, growing at a CAGR of 8.5% between 2023 and 2030. Growth drivers include increasing awareness, earlier diagnosis, and the rising prevalence of AVN worldwide.

Goals of the Collaboration

The collaboration will focus on enhancing outcomes for core decompression procedures, a standard approach to AVN management. Osteopore will apply its expertise in 3D-printed biomimetic and bioresorbable implants to design a novel scaffold-based implant that supports natural bone regeneration.

According to Osteopore, the implant design will undergo a series of laboratory tests during the collaboration, with the objective of reaching proof-of-concept validation by the end of the 12-month program. If successful, this could lead to first-in-human applications as part of the longer-term roadmap.

About Osteopore Limited

Founded in Singapore and listed on the Australian Securities Exchange, Osteopore Limited is a global leader in regenerative medicine technologies. The company develops and commercialises 3D-printed, bioresorbable implants designed to enable natural bone healing. Its patented micro-structured scaffolds are applied across multiple therapeutic areas, including craniofacial, orthopaedic, and dental surgery.

Through this collaboration, Osteopore aims to expand its clinical portfolio into AVN treatments, complementing its existing focus on bone regeneration.